Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec 10;7(3):367-368.
doi: 10.1016/j.ijwd.2020.12.004. eCollection 2021 Jun.

Identifying biosimilar side effects: Infliximab-dyyb-associated subcorneal pustular dermatosis

Maria Amoreth R Gozo  1 , Iviensan F Manalo  2 , Tunisia Cornelius  3
Affiliations
Case Reports

Identifying biosimilar side effects: Infliximab-dyyb-associated subcorneal pustular dermatosis

Maria Amoreth R Gozo et al. Int J Womens Dermatol. .

Erratum in

  • Erratum regarding previously published articles.
    [No authors listed] [No authors listed] Int J Womens Dermatol. 2021 Sep 28;7(5Part B):868. doi: 10.1016/j.ijwd.2021.09.012. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35028406 Free PMC article.
No abstract available

Keywords: Adverse reactions; Biosimilar; Infliximab; Infliximab-dyyb; Side effects; Subcorneal pustular dermatosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient's left foot and leg upon initial presentation to dermatology clinic: examination revealed diffuse scattered follicular papules on the arms, legs, and trunk.
Fig. 2
Fig. 2
Patient's right foot and leg upon initial presentation to dermatology clinic demonstrating blister formation on the right dorsolateral foot.
See this image and copyright information in PMC

References

    1. Bui L.A., Taylor C. Developing clinical trials for biosimilars. Semin Oncol. 2014;41(Suppl. 1):S15–S25. - PubMed
    1. Khraishi M., Stead D., Lukas M., Scotte F., Schmid H. Biosimilars: a multidisciplinary perspective. Clin Ther. 2016;38(5):1238–1249. - PubMed
    1. Kretschmer L., Maul J.-T., Hofer T., Navarini A. Interruption of Sneddon-Wilkinson subcorneal pustulation with infliximab. Case Rep Dermatol. 2017;9(1):140–144. - PMC - PubMed
    1. McKinnon R., Ward M. Safety considerations of biosimilars. AustPrescr. 2016;39(6):188–189. - PMC - PubMed
    1. U.S. Food and Drug Administration. Report a problem to the Center for Biologics Evaluation and Research [Internet]. 2020 cited 2020 April 21]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologi....

Publication types